首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Apurinic/Apyrimidinic endonuclease 1 regulates inflammatory response in macrophages.
【24h】

Apurinic/Apyrimidinic endonuclease 1 regulates inflammatory response in macrophages.

机译:Apurinic / Apyrimidinic内切核酸酶1调节巨噬细胞的炎症反应。

获取原文
获取原文并翻译 | 示例
           

摘要

The multi-functional apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) DNA repair and redox signaling protein has been shown to have a role in cancer growth and survival, however, little has been investigated concerning its role in inflammation. In this study, an APE1 redox-specific inhibitor (E3330) was used in lypopolysaccharide (LPS)-stimulated macrophages (RAW264.7). E3330 clearly suppressed secretion of inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin (IL-6) and IL-12 and inflammatory mediators nitric oxide (NO) as well as prostaglandin E(2) (PGE(2)) from the LPS-stimulated RAW264.7 cells. These data were supported by the down-regulation of the LPS-dependent expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) genes in the RAW264.7 cells. The effects of E3330 were mediated by the inhibition of transcription factors nuclear factor-kappaB (NF-kappaB) and activator protein 1 (AP-1) in the LPS-stimulated macrophages, both known targets of APE1. In conclusion, pharmacological inhibition of APE1 by E3330 suppresses inflammatory response in activated macrophages and can be considered as a novel therapeutic strategy for the inhibition of tumor-associated macrophages.
机译:多功能的嘧啶二酮内切核酸酶1 /氧化还原因子-1(APE1 / Ref-1)DNA修复和氧化还原信号蛋白已被证明在癌症的生长和存活中起作用,然而,关于其在炎症中的作用的研究很少。在这项研究中,APE1氧化还原特异性抑制剂(E3330)用于脂多糖(LPS)刺激的巨噬细胞(RAW264.7)。 E3330明显抑制了炎症细胞因子的分泌,包括肿瘤坏死因子-α(TNF-alpha),白介素(IL-6)和IL-12和炎性介质一氧化氮(NO)以及前列腺素E(2)(PGE(2) )来自LPS刺激的RAW264.7细胞。这些数据得到了RAW264.7细胞中诱导型一氧化氮合酶(iNOS)和环氧合酶-2(COX-2)基因LPS依赖性表达下调的支持。 E3330的作用是通过抑制LPS刺激的巨噬细胞(这是APE1的靶标)中的转录因子核因子-κB(NF-kappaB)和激活蛋白1(AP-1)介导的。总之,E3330对APE1的药理抑制作用抑制了活化巨噬细胞的炎症反应,可以被认为是抑制肿瘤相关巨噬细胞的一种新型治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号